Assessment of Asymptomatic Heart Disease in Children With HIV
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00426374|
Recruitment Status : Unknown
Verified January 2007 by Hadassah Medical Organization.
Recruitment status was: Not yet recruiting
First Posted : January 24, 2007
Last Update Posted : February 1, 2007
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Procedure: echocardiography and blood test||Not Applicable|
Human immunodeficiency virus (HIV) infection affects nearly 40 million adults and children worldwide. Recently introduced new antiviral drugs have significantly improved survival of patients with HIV infection. As mortality declines, morbidity becomes a concern. Heart disease is present in 20% of children and adults with HIV. The cardiac diseases include left ventricular dysfunction, hypertrophy and dilation, pericardial effusion and intracardiac masses. Cardiac disease is an independent risk factor for death in these children. The reported two-year survival of children with congestive heart failure is zero compared to 17% when no heart failure is present. It is thus indicated to perform periodic cardiac examinations in these patients, and early recognition of cardiac disease is paramount.
In addition to the traditional tools to assess cardiac status which include history, physical examination, ECG, chest X-ray and echocardiography, we propose to check biochemical markers. Brain natriuretic peptide has been shown to be a very sensitive marker for symptomatic and asymptomatic cardiac dysfunction, prognosis, severity of the disease and response to therapy in adults. Troponin-T is a very good marker for cardiac ischemia. Recently, we have found troponin-T to be a good marker for acute cardiac insult in infants and children.
The aim of this study is to perform screening of children with HIV predominantly clade C for cardiac disease using the above mentioned means.
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of the Cardiac Complications in Congenitally HIV-1 Infected Children in Israel by the Echocardiography and Measurement of N-Terminal Pro-B-Type Natriuretic Peptide (N-BNP).|
|Study Start Date :||January 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00426374
|Contact: Diana Averbuch, MDfirstname.lastname@example.org|
|Contact: Hadas Lemberg, PhD||00 972 2 email@example.com|
|Hadassah University Hospital, Pediatric Department, Pediatric AIDS Center|
|Jerusalem, Israel, 91120|
|Contact: Diana Averbuch, MD 972-50-7874940 firstname.lastname@example.org|
|Contact: Dan Engelhard, MD 972-2-6778960 email@example.com|
|Principal Investigator: Diana Averbuch, MD|
|Principal Investigator: Dan Engelhard, MD|
|Sub-Investigator: Amiram Nir, MD|
|Sub-Investigator: Azaria Rein, MD|
|Principal Investigator:||Diana Averbuch, MD||Hadassah University Hospital, Jerusalem, Israel|